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Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment.
Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly be conducted. Targeted
therapeutic treatment approaches and potentially immunotherapy based on a biological rationale may provide an alternative
strategy. We therefore subjected 70 urachal adenocarcinomas to targeted next-generation sequencing, conducted in situ and
immunohistochemical analyses (including PD-L1 and DNA mismatch repair proteins [MMR]) and evaluated the microsatellite
instability (MSI) status. The analytical findings were correlated with clinicopathological and outcome data and Kaplan-Meier
and univariable/multivariable Cox regression analyses were performed. The patients had a mean age of 50 years, 66% were
male and a 5-year overall survival (OS) of 58% and recurrence-free survival (RFS) of 45% was detected. Sequence variations
were observed in TP53 (66%), KRAS (21%), BRAF (4%), PIK3CA (4%), FGFR1 (1%), MET (1%), NRAS (1%), and PDGFRA (1%).
Gene amplifications were found in EGFR (5%), ERBB2 (2%), and MET (2%). We detected no evidence of MMR-deficiency (MMR-
d)/MSI-high (MSI-h), whereas 10 of 63 cases (16%) expressed PD-L1. Therefore, anti-PD-1/PD-L1 immunotherapy approaches
might be tested in UrC. Importantly, we found aberrations in intracellular signal transduction pathways (RAS/RAF/PI3K) in
31% of UrCs with potential implications for anti-EGFR therapy. Less frequent potentially actionable genetic alterations were
additionally detected in ERBB2 (HER2), MET, FGFR1, and PDGFRA. The molecular profile strengthens the notion that UrC is a
distinct entity on the genomic level with closer resemblance to colorectal than to bladder cancer.
Introduction
Urachal cancer (UrC) is a rare but aggressive cancer. It is
derived from the urachus, an embryological structure extend-
ing from the allantois to the fetal bladder. The urachus usu-
ally degenerates to form a ﬁbromuscular cord running from
the dome of the urinary bladder to the umbilicus, where it
forms the median umbilical ligament. Incomplete obliteration
occurs in up to 32% of adults but is usually microscopic and
asymptomatic.1
Approximately 90% of UrC are adenocarcinomas that
show remarkable histomorphological similarities with both
primary bladder adenocarcinoma and colorectal adenocarci-
noma (CRC), which represent the main differential diagnostic
entities.2 The correct differentiation of these entities is impor-
tant, as therapeutic options differ. While localized UrC is
usually treated by partial cystectomy and en bloc removal of
the umbilical ligament and umbilicus, primary bladder ade-
nocarcinoma usually requires radical cystectomy, and CRC
growing into the bladder requires either additional surgical
management of the primary tumor or palliative management.
A signiﬁcant proportion of UrC cases require further ther-
apy due to recurrent and/or metastatic disease in 21–48%.2
This calls for effective systemic therapy regimes, while radio-
therapy has only a limited role.3 Chemotherapy has tradition-
ally been chosen in analogy to urothelial bladder cancer due
to its close anatomical relation. However, non-bladder cancer
inspired regimens including 5-Fluorouracil (5-FU) like in
CRC show more favorable characteristics in advanced UrC.2
In addition, recent molecular data and positive results
from the ﬁrst targeted therapies point towards therapeutic
similarities between UrC and CRC. Like in CRC, oncogenic
signaling in UrC appears to employ preferably the epidermal
growth factor receptor (EGFR)/mitogen-activated protein
kinase (MAPK) and phosphoinositide 3-kinase (PI3K) path-
ways. Moreover, anti-EGFR agents such as cetuximab seem
to exert positive effects.4–6
To date, genetic data on UrC still is scant or reported
only in few cases.4,5,7–12 In addition, data on non-adenocarci-
noma UrC is completely lacking. We therefore analyzed a large
cohort of urachal adenocarcinomas in a targeted sequencing
approach supplemented with in situ and protein expression
analyses including evaluation of PD-L1 expression and evalua-
tion of the MMR/MSI status. In addition, a small subset of
non-adenocarcinoma UrCs was also analyzed. We aimed to
gain more insight in potentially targetable molecular alterations
of UrC to eventually facilitate targeted therapy and/or immuno-
therapy decision-making.
Material and Methods
Cohorts and clinicopathological data
Due to the rarity of UrC, an international, multi-institutional
approach was chosen and two cohorts were created.
What’s new?
Urachal cancer (UrC) is a rare but aggressive cancer. In this study, the authors analyzed a number of genes and proteins that
might be altered in UrC. They found no evidence of unusual mismatch repair (MMR) or microsatellite instability (MSI) status.
However, they did observe aberrations in PD-L1-status, and in intracellular signal-transduction pathways (RAS/RAF/PI3K), as
well as alterations in ERBB2 (HER2), MET, FGFR1, and PDGFRA. These results might provide a basis for targeted and/or immu-
notherapeutic approaches.
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
Reis et al. 1765
Int. J. Cancer: 143, 1764–1773 (2018) VC 2018 UICC
The ﬁrst cohort included formalin-ﬁxed parafﬁn embed-
ded (FFPE) urachal adenocarcinoma samples from 41
patients from nine centers: University Hospital Essen (Ger-
many),4 Semmelweis University Budapest (Hungary), Univer-
sity of G€ottingen (Germany), University Hospital/RWTH
Aachen University (Germany), University of Bonn (Ger-
many), Jagiellonian University Cracow (Poland), University
Hospital of Rennes (France), Institute of Pathology of Trier
(Germany), and the Vancouver Prostate Center (Canada).
Additionally, four cases of non-adenocarcinoma histology
(n 5 2: squamous cell carcinoma (SCC); n 5 1: urothelial
carcinoma (UC), n 5 1: undifferentiated carcinoma) were
available and analyzed.
The second, national Dutch cohort included FFPE samples
from 29 patients with urachal adenocarcinomas from the
Netherlands Cancer Institute (NKI) in Amsterdam (The
Netherlands).
Diagnosis of urachal cancer was established after consider-
ation of multi-disciplinary results. Histopathology was evalu-
ated in accordance with (adapted) WHO-criteria13–15 and
review of available material was conducted. Data was requested
from cooperating institutions using a standardized 42 parame-
ter datasheet.
The ﬁrst international multi-institutional cohort was analyzed
at the University Hospital Essen (Institute of Pathology) and the
second national Dutch cohort at the Netherlands Cancer Insti-
tute (NKI) in Amsterdam.
Clinicopathological data was collected retrospectively by chart
review and from epidemiological databases. Clinical follow-up of
patients varied by tumor stage and individual institutional rou-
tines. Overall survival (OS) was deﬁned as the time from diag-
nosis to death from any cause. Recurrence-free survival (RFS)
was deﬁned as the time to occurrence of metastatic disease and/
or local recurrence. The study is in accordance with the princi-
ples embodied in the Declaration of Helsinki. It was approved
before start of experiments by the ethics committee of the Medi-
cal Faculty of the University of Duisburg-Essen (16–6902-BO)
and included collection of external tumor samples for analyses.
The Translational Research Board of the Netherlands Cancer
Institute – Antoni van Leeuwenhoek Hospital (CFMPB310)
additionally approved analysis of the Dutch cohort.
Targeted next-generation sequencing (NGS)
Customized NGS panels were used to cover important known
actionable driver mutations/alterations from CRC, UC and
additional main cancer entities (15/13 gene panels; Support-
ing Information Tables S1–S3).
A detailed description of sample processing, DNA extrac-
tion, sequencing and data analysis can be found in Support-
ing Information Document S1. In brief, in both cohorts
representative FFPE tumor tissue blocks were selected and
DNA was extracted. After target enrichment, libraries were
sequenced on an Illumina MiSeq platform (ﬁrst cohort,
Essen) and Illumina Hiseq 2500 platform (second cohort,
Amsterdam) followed by mapping to the human genome
(version hg19), data ﬁltering and reporting of all non-benign,
non-SNP variants found in Cosmic and/or Clinvar (selection
of pathogenic alterations).
In situ hybridization (ISH) assays
In cases with evidence for gene ampliﬁcation detected by
NGS (fold change: 3.5) in the ﬁrst cohort, the ﬁndings were
validated by ISH (ERBB2: chromogen ISH (CISH), EGFR/
MET: ﬂuorescence ISH [FISH]) followed by immunohisto-
chemistry (IHC). Further details can be found in Supporting
Information Document S1.
Immunohistochemistry
p53-IHC analyses were done from available FFPE material
from the cohort of Essen (n 5 12). PD-L1 analyses were per-
formed using clone 22C3 and MMR-status was determined
by MLH1-, MSH2-, MSH6, and PMS2-IHC. MMR-IHC
results of a subset of cases (n 5 12) has been published.16
Due to the limited amount of tissue available, further IHC-
assays (HER2, EGFR, and c-MET) were restricted to cases
with signs of gene ampliﬁcation in NGS- and ISH-analyses.
Further details can be found in Supporting Information Doc-
ument S1 and Table S4.
Microsatellite instability (MSI) analyses
In brief, multiplexed PCRs were performed using ﬁve pri-
mers. MSI-h was deﬁned as the presence of two or more
unstable microsatellite markers. Further details can be found
in Supporting Information Table S5.
Statistical analyses
Statistical analyses were conducted with SPSS (v23; IBM,
Armonk, NY). The Chi square-test, t test or Spearman corre-
lation was used when appropriate. Kaplan-Meier survival
analyses with the log-rank test were performed to assess the
impact of selected variables on OS and RFS. In addition, uni-
variable/multivariable Cox regression analyses were con-
ducted (inclusion criteria for multivariable analysis: p  0.05
in univariable analysis). p-values  0.05 were assumed statis-
tically signiﬁcant, while p-values  0.1 were designated as
trends. Genetic alterations were visualized using the Onco-
Printer (v.1.0.1) and MutationMapper (v1.0.1) tools.17,18
Results
Clinicopathological and prognostic characteristics of
urachal adenocarcinomas
Detailed clinicopathological and survival data of the 70 ana-
lyzed urachal adenocarcinomas are shown in Tables 1 and 2.
Both cohorts were well-balanced in terms of clinicopathologi-
cal characteristics.
Data on follow-up was available in 64 of the 70 patients
(91.4%) with urachal adenocarcinomas. The median follow-up
was 49 months (range: 2–212 months). The 5-year OS and RFS
rates were 58% and 45% respectively, with a median OS of 109
months (SE: 29.9) and median RFS of 50 months (SE: 13.0).
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Genomic alterations in urachal adenocarcinomas
Detailed information is shown in Figure 1, Supporting Infor-
mation Document S1, Figure S1, and Table S2.
Overall, 73 pathogenic mutations and four gene ampliﬁca-
tions were detected in the 70 analyzed urachal adenocarcinomas.
At least one genomic alteration was found in 55 of 70 patients
(79%). All reported mutations were predicted to be pathogenic.
Missense mutations were the most common type of alter-
ation (n 5 64), followed by truncating mutations (n 5 4),
and nonsense mutations (n 5 2). There was one deletion,
one insertion and one splice-site mutation.
Two of the four patients with gene ampliﬁcations were
female (50%), three were intestinal type UrC (EGFR-ampli-
ﬁed: n 5 2, ERBB2-ampliﬁed: n 5 1), one was a signet ring
Table 1. Clinicopathological data in relation to mutational data
Table 1 n (%)
Any mutation MAPK/PI3K alterated
Yes (n) Yes % p Yes (n) Yes % p
Sex Female 24 (34) 18 75 0.920 9 38 0.433
Male 46 (66) 35 76 13 28
Total 70 53 76 22 31
Age median (min, max) 50 (24, 78) – – –
UrC type Intestinal 30 (43) 24 80 0.499 10 33 0.846
Mucinous 26 (37) 18 69 8 31
NOS 5 (7) 4 80 1 20
Signet ring 4 (6) 4 100 1 25
Mixed 5 (7) 3 60 2 40
Total 70 53 76 22 31
Signet ring cells Yes 11 (17) 10 91 0.202 3 27 0.725
No 55 (83) 40 73 18 33
Total 66 50 76 21 32
Sheldon I 0 (0) 0 0 0.165 0 0 0.609
II 8 (12) 5 63 2 25
IIIA 28 (41) 20 71 10 36
IIIB 5 (7) 3 60 1 20
IIIC 1 (2) 1 100 1 100
IIID 1 (2) 1 100 0 0
IVA 5 (7) 4 80 1 20
IVB 20 (29) 17 85 5 25
Total 68 51 75 20 29
Mayo I 17 (28) 10 59 0.073 4 24 0.877
II 19 (31) 14 74 8 42
III 5 (8) 4 80 1 20
IV 20 (33) 17 85 5 25
Total 61 45 74 18 30
LN status N0 28 (48) 19 68 0.321 9 32 0.942
N1 12 (21) 10 83 4 33
No LND 18 (31) 15 83 5 28
Total 58 44 76 18 31
Dist. met. M0 42 (68) 31 74 0.355 13 31 0.795
M1 20 (32) 17 85 5 25
Total 62 48 77 18 29
Mutational data is separately displayed for cases with any detected mutation and for cases with MAPK/PI3K-pathway activation (mutations in intra-
cellular signal transduction pathways). Detailed clinicopathological data separately displayed for both cohorts can be found in Supporting Informa-
tion Table S3.
Abbreviations: UrC, urachal cancer, LN, lymph node, Dist. met., distant metastasis, NOS, not otherwise specified, LND, lymph node dissection.
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cell type UrC (MET-ampliﬁed; Supporting Information Fig. S2)
and all were alive at last follow-up.
Activating MAPK/PI3K-alterations were common events
in urachal adenocarcinomas with 22 mutations in K-/NRAS,
BRAF or PIK3CA affecting 22 of 70 patients (31%; Fig. 1,
Supporting Information Fig. S1). These alterations were
mutually exclusive, whereas in 16 of 22 cases (73%) a con-
comitant TP53 mutation was detected. All mutations affected
functional regions with predicted pathogenicity (Supporting
Information Fig. S1).
Table 2. Univariable (a) and multivariable (b) Cox-analyses in the total cohort of urachal adenocarcinomas
Table 2a
Overall survival (OS) Recurrence-free survival (RFS)
HR 95% CI p HR 95% CI p
Sex Female ref. ref.
Male 0.801 0.327–1.958 0.626 1.462 0.591–3.614 0.411
Age 50 years ref. ref.
>50 years 0.725 0.319–1.647 0.443 0.607 0.282–1.304 0.201
UrC type: intestinal No ref. ref.
Yes 0.589 0.253–1.369 0.218 0.488 0.222–1.074 0.075
UrC type: mucinous No ref. ref.
Yes 1.649 0.740–3.677 0.222 1.189 0.566–2.497 0.648
Signet ring cells No ref. ref.
Yes 2.148 0.832–5.548 0.114 1.725 0.685–4.345 0.247
Sheldon stage IIIa ref. ref.
>IIIb 2.405 1.060–5.456 0.036 1.801 0.858–3.782 0.120
Mayo stage I ref. ref.
II 4.497 1.320–15.313 0.016 2.513 0.943–6.696 0.065
LN status N0 ref. ref.
N1 2.888 1.065–7.828 0.037 4.565 1.615–12.902 0.004
Dist. met. M0 ref. ref.
M1 2.43 1.085–5.441 0.031 1.564 0.701–3.493 0.275
Any mutation No ref. ref.
Yes 2.56 0.762–8.596 0.128 0.922 0.390–2.180 0.854
MAPK/PI3K alterated No ref. ref.
Yes 0.812 0.320–2.061 0.661 0.897 0.396–2.033 0.795
Table 2b
Overall survival (OS) Recurrence-free survival (RFS)
HR 95% CI p HR 95% CI p
Sheldon stage (IIIa/>IIIb) 2.203 0.965–5.026 0.061 LN Stage (N0/N1) 2.462 0.757–8.013 0.134
Any mutation (no/yes) 2.216 0.653–7.517 0.202 Any mutation (no/yes) 1.343 0.279–6.471 0.713
Sheldon stage (IIIa/>IIIb) 2.384 1.043–5.450 0.039 LN Stage (N0/N1) 2.841 0.836–9.663 0.094
MAPK/PI3K altered (no/yes) 0.931 0.363–2.391 0.882 MAPK/PI3K altered (no/yes) 0.362 0.067–1.945 0.236
Mayo stage (I/II) 4.035 1.171–13.909 0.027 –
Any mutation (no/yes) 1.81 0.525–6.243 0.348 –
Mayo stage (I/II) 4.563 1.337–15.577 0.015 –
MAPK/PI3K altered (no/yes) 0.846 0.326–2.196 0.732 –
OS-related multivariable analysis models were calculated for Sheldon and Mayo stages separately (both p < 0.05 in univariable analysis). As both
staging systems include information on status of lymph nodes and distant metastasis, these factors were excluded from OS-related models. For
RFS, only lymph node status exhibited a p values < 0.05 in univariable analyses. Therefore, RFS models have been calculated separately including
lymph node status.
Abbreviations: HR, hazard ratio, CI, confidence interval, LN, lymph node, Dist. met., distant metastasis.
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Figure 1. Oncoprints of the genetic alterations in UrC. (A) Overview of the genetic alterations detected in the total cohort urachal adenocar-
cinomas. (B) A more detailed version including information on sex, histology, PD-L1 expression and genetic alteration type also in the non-
adenocarcinoma UrC cases. Gene amplifications (including ERBB2*, n 5 41/70) were evaluated in the first cohort only. Details on the
genetic events can be found in Supporting Information Table S2. Abbreviations: NOS, not otherwise specified; SCC, squamous cell carci-
noma; TPS, PD-L1 tumor proportion score; UC, urothelial carcinoma; UD, undifferentiated carcinoma. mucinous*: cases with predominant
signet ring cell morphology included. [Color figure can be viewed at wileyonlinelibrary.com]
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The ﬁrst, multi-institutional cohort showed more KRAS
mutations (p 5 0.059). No other signiﬁcant differences regard-
ing molecular alterations between both cohorts were noted. In
particular, there were no statistically signiﬁcant differences in
clinico-pathological or in any molecular parameters between
mucinous and intestinal type urachal carcinomas.
In 66 of 70 cases (94.3%) tissue for MMR-IHC was avail-
able with technical feasibility of IHC of all four proteins
(MLH1, MSH2, MSH6, and PMS2) in 61 of 70 cases (87.1%).
The molecular MSI-analyses were feasible in 56 of 70 cases
(80%). A negative MMR expression was detected in one case
(MSH2). In this and all other cases, all remaining MMR-
markers were positive and no MSI-h was detected.
In 63 of 70 cases (90%) sufﬁcient material was available for
PD-L1-IHC. In 10 of these 63 cases (15.9%) a speciﬁc PD-L1-
expression in the tumor cells was detectable (Fig. 1) with a
tumor proportion score (TPS) of 1–49% in 9 of 10 cases (90%)
and a TPS  50% in one Case (10%). PD-L1-expression was
not restricted to intestinal type UrC (3/10; 30%). The majority
of PD-L1 expressing cases were found in mucinous type UrC
(7/10; 70%) including the only case with high PD-L1-expression
(TPS  50%). No obvious clustering of cases with PD-L1-
expression and other molecular events was obvious. However,
both cases with MET-alterations exhibited PD-L1 expression.
Correlation between genomic alterations and clinical
outcomes
Clinicopathological factors were not associated with any genetic
event, except for a trend to higher Mayo tumor stage in UrC
with MAPK/PI3K-alterations (p 5 0.073). Organ conﬁned dis-
ease, that is Sheldon19 Stage IIIA and Mayo20 Stage I, and
absence of metastatic disease were univariable predictors of more
favorable OS (p 5 0.036, p 5 0.016, p 5 0.037/p 5 0.031) while
only absence of lymph node metastasis predicted better RFS
(p 5 0.004) in univariable analysis. A trend to more favorable
RFS was found in intestinal type UrC (p 5 0.075; log-rank test:
p 5 0.068, Supporting Information Fig. S3) and in organ con-
ﬁned disease in the Mayo system (p 5 0.056).
Presence of PD-L1 expression was associated with adverse
PFS (p 5 0.002; log-rank test), however, there were only
three events in the PD-L1 positive group, thus limiting its
signiﬁcance. No such association was detected regarding OS.
In multivariable Cox-analyses for OS and RFS, presence
of any mutation or MAPK/PI3K-alteration did not exhibit
prognostic inﬂuence (Table 2).
Additionally, no correlation was observed between the muta-
tional status of TP53 and its IHC staining pattern. A higher rate
of TP53 mutation was observed in UrC with signet ring cells
(p 5 0.05). No other clinicopathological or prognostic associa-
tions were noted for TP53 and/or KRAS mutational status.
Results in non-adenocarcinoma UrC
The results of the four cases of non-adenocarcinoma UrC are
included in Figure 1 and Supporting Information Table S2.
Due to the low number of cases, no correlation analyses with
clinicopathological data were performed.
Discussion
Systemic therapy is often required in UrC because patients
present with advanced stage disease or they progress after
initial locoregional intervention. Investigation of the efﬁcacy
of chemotherapy has been limited to retrospective series. Due
to the rarity of UrC, it is not feasible to perform large pro-
spective clinical studies to evaluate the clinical beneﬁt of vari-
ous systemic therapies. Molecular alterations, however, may
provide the rationale for targeted therapeutic approaches
and/or immunotherapy.
The most common genetic alterations in urachal adeno-
carcinomas we detected were TP53 mutations (66%). This
high number indicates the common role of inactivation of
this tumor suppressor gene also in UrC. Although TP53 has
in the past been considered mostly undruggable, recently
multiple efforts of targeting TP53 altered tumors are in
development.21
In addition, we found a subset of UrC characterized by
dysfunctional and activated oncogenic MAPK- and PI3K-
pathways.4,5 As EGFR signaling mainly occurs through these
pathways,6 we grouped together all UrC with any pathogenic
mutational event in KRAS, NRAS, BRAF, or PIK3CA
(n 5 22; 31%). This subset is additionally equivalent to all
UrCs with mutations in intracellular signal transduction
pathways and was termed ‘MAPK/PI3K-altered’ subset. All
these alterations were mutually exclusive.
These ﬁndings together with the results of the MMR-/
MSI- and PD-L1-analyses have important therapeutic and
ontogenetic implications.
Due to histopathological and certain clinical similarities of
UrC and CRC, chemotherapy in advanced UrC has often
been adapted from CRC with 5-FU containing approaches.
This has been shown to be more effective compared to
regimes used for UC.2,22 In accordance with this observation,
we did not ﬁnd evidence of MMR-d/MSI-h in UrC, which
leads to a hypermutated phenotype and in CRC has been
implicated in decreased 5-FU-efﬁcacy.23 Our single UrC-case
with immunohistochemical MSH2-loss seems to represent a
false negative result, as MSH6-protein expression was
retained which should not be the case in MSH2-deﬁcient
tumors.7 Additionally, no evidence of MSI-h was detected on
the DNA level by microsatellite PCR analyses neither in this
nor in any other case.
Another recent and efﬁcient anti-cancer strategy is target-
ing tumoral immune-escape mechanisms, in which inhibitors
of the PD-1/PD-L1-axis are of particular therapeutic interest.
PD-1/PD-L1 inhibitors have proven efﬁcacy in several types
of advanced cancer, including melanoma, non-small-cell lung
cancer, renal cell carcinoma and bladder cancer.24 In most
studies, cases with immunohistochemical PD-L1-expression
on tumor cells and/or tumor-related immune-cells exhibited
better responsiveness to PD-1/PD-L1-inhibitors. However, as
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also in tumors without PD-L1-expression positive anti-
tumoral effects can be detected, PD-L1-IHC testing is consid-
ered complementary with the exception of the companion
diagnostic 22C3-test in NSCLC.24 With regard to UrC, these
results implicate that PD-1/PD-L1-inhibitors might be effec-
tive in advanced disease despite its modest rate of PD-L1-
expression (16%). In fact, others have recently reported on a
case in UrC with atezolizumab-therapy, an anti-PD-L1-
antibody, resulting in stable disease.25 However, as MMR-d/
MSI-h does not seem to be a hallmark of UrC at least in our
cohort, immune escape mechanisms employing the PD-1/
PD-L1 axis do not seem to be the deﬁning molecular charac-
teristic of UrC. This also has implications for the use of pem-
brolizumab in UrC, an anti-PD-1-antibody, which recently
gained FDA-approval in MMR-d/MSI-h tumors irrespective
of site of origin.
Therefore, targeted therapy approaches are of prominent
therapeutic interest in advanced UrC.
Recently, Collazo-Lorduy and colleagues reported a suc-
cessful application of cetuximab, an anti-EGFR monoclonal
antibody which is used in metastasized CRC, in one UrC
patient who was pretreated with chemotherapy. This treat-
ment was justiﬁed by the presence of an EGFR ampliﬁcation
and absence of a KRAS mutation.5
In CRC, it has been shown that MAPK-/PI3K-activation
downstream of the EGF receptor is associated with anti-
EGFR therapy resistance.26 We detected two cases in our
cohort with coexisting EGFR gene ampliﬁcation and with-
out activating MAPK-/PI3K-mutations thus EGFR ampliﬁ-
cation is a rare event in UrC. Therefore, it seems
reasonable to test for EGFR gene ampliﬁcations and acti-
vating MAPK/PI3K-pathway mutations in advanced UrC
when an anti-EGFR therapy is considered. This approach
would be similar to the concept of complementary/com-
panion diagnostics in CRC.27
In addition to these therapeutic considerations, the
mutational proﬁle of UrC shows similarities to that of
CRC. Most of the detected activating MAPK/PI3K-path-
way mutations were also common in CRC when compared
to The Cancer Genome Atlas (TCGA) data. 28 This is
especially prominent in the clustering of codon G12/G13
KRAS alterations but also for the remaining KRAS, NRAS,
and PIK3CA mutations (Supporting Information Fig. S1).28
Interestingly, both EGFR ampliﬁed cases we detected were
intestinal type UrCs.
However, not only similarities but also differences were
detected. For example, we identiﬁed three non-classical,
BRAF mutations (G469A: n 5 1, D594G: n 5 2) adding to
the four classical V600E mutations reported previously.4
While the G469A BRAF mutation was relatively common
in cancer, the D594G variant has rarely been detected in
cancer. Interestingly, although being located in the BRAF-
kinase region, the D594G variant has been described in a
case of metastatic CRC responding to cetuximab.27
In addition, a comparison with TCGA data for CRC
revealed lower frequencies of almost all analyzed genetic
alterations in UrC with the exception of TP53 mutations.
(Supporting Information Fig. S4).28 However, although cer-
tain differences to CRC are apparent, the disparity to UC is
more pronounced (Supporting Information Fig. S4). This
notion is further supported by the very low incidence of Tel-
omerase reverse transcriptase (TERT) promoter mutations in
urachal adenocarcinomas (4%), which is otherwise a very
common event in UC but not in CRC.29–31 Interestingly, our
ﬁndings regarding MMR-d/MSI-h in UrC are more compara-
ble to ﬁgures in UC32 than in CRC.23,28 Regarding the rate of
PD-L1-expression, UrC (16%) seems to be in the lower range
of ﬁgures reported for UC (14–28%)33 and CRC (9–
43%).34,35 Taken together, UrC appears to be a distinct entity
on the genomic level with closer resemblance to CRC than to
UC. Further analyses are needed to address this issue while
the present study was not primarily designed from an onto-
genetic point of view.
In addition to alterations related to intracellular signal
transduction pathways, we also detected cases with other
pathogenic and possibly targetable genetic events. For exam-
ple, pathogenic FGFR1, MET, and PDGFRA mutations and
MET- and ERBB2-gene ampliﬁcations were detected in one
case each, possibly identifying therapeutic targets in these
patients.
Interestingly, both UrC-cases with MET-alterations exhib-
ited PD-L1-expression and ﬁrst (pre-)clinical evidence of the
relationship between PD-L1 upregulation and MET-altera-
tions is emerging.36 Moreover, one case with high level
ERBB2 gene ampliﬁcation and HER2-protein expression was
detected (Supporting Information Fig. S2). HER2 is another
member of the EGFR family and a well-known therapeutic
target in breast and gastric cancer and under clinical investi-
gation in other cancers such as non-small cell lung
cancer.37–39
Our analysis has certain limitations. Due to the rarity of
the disease, prospective analyses can hardly be conducted.
We therefore chose a retrospective multi-institutional
approach to maximize our sample size. In addition, we ana-
lyzed a ﬁrst multi-institutional, international cohort and a
second national Dutch cohort at different sites. Through this
approach we expected to gain a more comprehensive and
homogenous estimation of genetic events in UrC. This
approach holds, however, the disadvantage of analytical dif-
ferences between laboratories. This applies to the use of
MiSeq and HiSeq-platforms at the different sites. While the
enhanced capabilities and sensitivity of the HiSeq-platform
are accepted, both sites were in contact to obtain best compa-
rable analytic data. Although our cohort is the largest ana-
lyzed in the literature, the case number remains low, which
precludes adequate statistical power for some sub-group anal-
yses. This is also important when considering the results of
survival analyses as inevitably the samples were collected
from patients with a range of different stages and treatments
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confounding the possible survival impact of genetic altera-
tions. Additionally, the employed gene panel was of modest
size which has to be kept in mind in regard to the patients
where no genomic aberration was detectable.
In conclusion, we have analyzed the largest cohort of UrC
to date in an international, multi-institutional targeted
sequencing approach supplemented with in situ hybridization
and protein expression analyses including evaluation of PD-
L1 expression and MMR/MSI-status. Although MMR-d/MSI-
h does not seem to be a hallmark of UrC, anti-PD-1/PD-L1
immune therapy might be a potential therapeutic option
given the PD-L1 expression rate in UrC. In particular, our
results underline the role of MAPK/PI3K-pathway dysregula-
tion which was detected in 31% of urachal adenocarcinomas.
This has important implications for possible anti-EGFR ther-
apy in UrC and suggests that targeted testing of MAPK/
PI3K-pathway alterations would be reasonable in patients
with advanced UrC before considering anti-EGFR therapy. In
addition, further potentially druggable alterations were found
in ERBB2 (HER2), MET, FGFR1, and PDGFRA in a subset of
patients. Our data support the notion of UrC being a distinct
entity on the genomic level with closer resemblance to CRC
than to UC.
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